Health
Johnson & Johnson’s (JNJ) COVID-19 vaccine would have an edge over others without this glitch – AlphaStreet
Johnson & Johnson (NYSE: JNJ) saw its shares climb 2% on Thursday after the company reported positive results from the early-stage trials of its COVID-19 vaccine a day ago. The stock has gained 9% in the past three months and over 8% in the past one year. The companys vaccine candidate has an advantage over its competitors in terms of dosage and storage but this is being hindered by manufacturing issues.
Trial results
On Wednesday, the results from J&Js interim Phase 1/2a trial were published in…
-
Noosa News20 hours agoProtest calls for shark net removal
-
General19 hours agoThree youths in police custody after fire at Ashley Youth Detention Centre in northern Tasmania
-
General5 hours agoAlleged Croydon Park gunman Artemios Mintzas charged with 25 offences
-
Noosa News22 hours agoNew playground equipment encourages children to learn through ‘risky play’